Clopidogrel is more effective than aspirin in preventing coronary artery reocclusion after thrombolysis.
Cardiovascular Research Laboratory, Texas Heart Institute/St. Luke's Episcopal Hospital, Houston.
S K
SK
Yao
J C
JC
Ober
J J
JJ
Ferguson
J P
JP
Maffrand
H V
HV
Anderson
L M
LM
Buja
J T
JT
Willerson
D000818:Animals; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects; D000077144:Clopidogrel; D003328:Coronary Thrombosis / Q000097:blood / Q000188:drug therapy*; D004195:Disease Models, Animal; D004285:Dogs; D004359:Drug Therapy, Combination; D006400:Hematocrit; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D066298:In Vitro Techniques; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D012008:Recurrence; D015912:Thrombolytic Therapy; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use
D010975:Platelet Aggregation Inhibitors; D006493:Heparin; D000077144:Clopidogrel; D010959:Tissue Plasminogen Activator; D013988:Ticlopidine; D001241:Aspirin